| Literature DB >> 24882752 |
Giovanni Meola1, Rosanna Cardani2.
Abstract
Myotonic dystrophy (DM) is the most common adult muscular dystrophy, characterized by autosomal dominant progressive myopathy, myotonia and multiorgan involvement. To date two distinct forms caused by similar mutations have been identified. Myotonic dystrophy type 1 (DM1, Steinert's disease) is caused by a (CTG)n expansion in DMPK, while myotonic dystrophy type 2 (DM2) is caused by a (CCTG)n expansion in ZNF9/CNBP. When transcribed into CUG/CCUG-containing RNA, mutant transcripts aggregate as nuclear foci that sequester RNA-binding proteins, resulting in spliceopathy of downstream effector genes. However, it is now clear that additional pathogenic mechanism like changes in gene expression, protein translation and micro-RNA metabolism may also contribute to disease pathology. Despite clinical and genetic similarities, DM1 and DM2 are distinct disorders requiring different diagnostic and management strategies. This review is an update on the recent advances in the understanding of the molecular mechanisms behind myotonic dystrophies. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.Entities:
Keywords: Clinical finding; Molecular mechanism; Muscle biopsy; Myotonic dystrophy type 1; Myotonic dystrophy type 2; Pathology
Mesh:
Substances:
Year: 2014 PMID: 24882752 DOI: 10.1016/j.bbadis.2014.05.019
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002